Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
about
Cytoreductive surgery in the era of targeted molecular therapyCytoreductive nephrectomy and its role in the present-day period of targeted therapy.Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.Are Allogeneic Blood Transfusions Associated With Decreased Survival After Surgery for Long-bone Metastatic Fractures?Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy.Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy.New challenges in kidney cancer management: integration of surgery and novel therapies.Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio.The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.Cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based analysis of perioperative outcomes according to clinical stage.Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma.
P2860
Q26774134-4C02CB79-3490-4B91-A634-84B9D2D75AB1Q26783520-C022472F-FD87-4FDC-8789-F0AE58157C0BQ33740717-FD098873-771B-4302-AF88-BEB8E2A10A21Q33843677-5F026EAD-1D65-4125-8F64-4DDFF862AC16Q35689262-BA580EFA-B521-43E7-8EB2-EDBF7CA65AB7Q38132624-59F43C7A-66FB-4E17-9E44-DFCFB6B10AF0Q38239937-EBD7DAE0-F41F-459A-B6B0-1C204329D7CAQ38381788-34E44A30-91C4-49AC-BAA7-335DA18A5EABQ38582600-BDCBC8A7-6C7C-44AD-8499-F0A65970754AQ39945553-F80AEFD5-2EDB-460D-9601-0CC262083C69Q40604822-5AFF81E2-ADF8-48F4-84DE-DDAE16A667EFQ40908884-72849B5B-61D7-4779-8494-4A3EA7742F24Q44217603-35F078DF-F700-4F8E-A4CB-6F064275CABDQ47207045-1A2F72A4-FFA7-41D5-B711-5DDCE00F381AQ47898943-248B0411-7119-4D9F-AD86-62F3477CB31AQ50727767-98DBEFDB-C20E-4F15-8A05-5F6EB07385C8
P2860
Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Development of accurate models ...... tastatic renal cell carcinoma.
@ast
Development of accurate models ...... tastatic renal cell carcinoma.
@en
type
label
Development of accurate models ...... tastatic renal cell carcinoma.
@ast
Development of accurate models ...... tastatic renal cell carcinoma.
@en
prefLabel
Development of accurate models ...... tastatic renal cell carcinoma.
@ast
Development of accurate models ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P1433
P1476
Development of accurate models ...... tastatic renal cell carcinoma.
@en
P2093
Christopher G Wood
Daniel D Sjoberg
E Jason Abel
Michael Rink
Nizar M Tannir
Pheroze Tamboli
Shahrokh F Shariat
Stephen H Culp
Vitaly Margulis
Yury Rapoport
P2860
P304
P356
10.1016/J.EURURO.2012.11.040
P407
P577
2012-11-23T00:00:00Z